Qardio said today that its remote patient monitoring tech, QardioMD, will work with any provider that uses Redox to exchange healthcare data.
The partnership will enable remote care delivery and translate electronic health record (EHR) data into information for clinical decision-making, according to the companies.
Get the full story on our sister site, Medical Design & Outsourcing.
Qardio this week announced that it received FDA 510(k) clearance for its QardioCore ambulatory ECG device.
QardioCore is an extension of Qardio’s remote patient monitoring platform used for primary care and hypertension monitoring to acute care and cardiology.
The device requires no special skin preparation, gels, adhesives or patches. It can be easily self-fit, removed and re-fit by a patient and does not require an in-clinic fitting.
“Our goal for QardioCore has always been to create a better experience for patients and care providers. For patients, there is much less inconvenience in comparison to traditional monitors. For providers, patient usability leads to compliance – so QardioCore can deliver high diagnostic yields by design,” cofounder Rosario Iannella said in a news release.
QardioCore is designed to capture continuous ECG rhythms. QardioCore and its QardioMD display full disclosure ECG reports and can be used under th…